09-01-2023
The Fifth John Gorman Lectureship at the “Birth 2022 Congress”
Read all
These Conferences in Transfusion Medicine are made possible thanks to the unconditional support of Kedrion Biopharma
02-09-2022
Permira Funds and the Marcucci family complete investment in Kedrion & BPL
Read all
Announced appointment of Ugo Di Francesco as CEO
28-06-2022
Kedrion Biopharma Recognized for Innovation in Treating Rare Disease
Read all
RYPLAZIM® is the first FDA Approved Treatment for Plasminogen Deficiency Type 1